A recent study suggests that individuals who discontinue new GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who halt conventional lifestyle regimens.
Published data in a prominent health publication points out that while overweight people frequently drop substantial amounts of their body weight while using the jabs, the weight returns at an estimated rate of nearly a kilo each month upon discontinuation.
"People purchasing these treatments should be cognizant of the potential of fast weight regain when the medication ends," warns lead investigator Dr. Susan Jebb.
This pace of regain means a return to starting mass in about 18 months.
Comparing Approaches
The study, which looked at 37 of trials involving over 9,000 of participants, contrasted the results of the injectable medications with older methods.
The team note that people who lose weight through lifestyle changes alone usually see a less rapid weight regain—around 100 grams monthly—once they finish.
The Reason for the Quick Rebound
Nutrition scientists suggest the mechanism of the injections is key to understanding the accelerated weight return.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which controls appetite.
"Artificially providing GLP-1 concentrations far above than the body's typical production might result in the system to produce less of its own natural GLP-1, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' leads to appetite is uncontrolled, making overeating far more likely."
A Lifelong Disease?
Health authorities suggest the jabs for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
Many experts argue that, due to the high risk of weight regain, the therapy should be considered life-long.
This perspective is supported by drug manufacturers, who say that the results "highlight the persistent nature of obesity," akin to managing conditions like hypertension.
Patient Accounts
Users who have stopped the jabs describe a sudden resurgence of hunger.
"It was like a trigger activating and I was suddenly extremely hungry," recalled one woman.
The struggle is exacerbated if users have not adopted permanent lifestyle or habit modifications during treatment.
Widespread Adoption
Survey data indicate that millions of people in the UK have used these injections in the past year, with demand being substantial.
- Adoption is greater among women compared to men.
- The middle-aged demographic shows the highest usage rates.
- Many access the drugs through private healthcare rather than the NHS.
Finally, clinicians caution that while the jabs are powerful tools for weight loss, they are not a permanent cure and lasting health benefits relies on combined behavioural management.
